Covered recipient · General Payments record
AYMAN S ALZUBI
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2019–2024
$1,432.69
- Reported across 86 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $424.72 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $255.98 | 11 |
| Janssen Biotech, Inc. | $89.14 | 3 |
| AIMMUNE THERAPEUTICS, INC. | $24.76 | 1 |
| Phathom Pharmaceuticals, Inc. | $20.91 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.99 | 1 |
| Gilead Sciences, Inc. | $15.94 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $4.72 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216355 | CMS |
| ABBVIE INC. | $19.50 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216357 | CMS |
| ABBVIE INC. | $7.59 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216359 | CMS |
| ABBVIE INC. | $19.94 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216361 | CMS |
| ABBVIE INC. | $6.61 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216363 | CMS |
| ABBVIE INC. | $6.71 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216365 | CMS |
| ABBVIE INC. | $13.09 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216367 | CMS |
| ABBVIE INC. | $21.41 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216369 | CMS |
| ABBVIE INC. | $23.92 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216371 | CMS |
| ABBVIE INC. | $16.42 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216373 | CMS |
| ABBVIE INC. | $116.07 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103216375 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $24.76 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146977548 | CMS |
| Gilead Sciences, Inc. | $15.94 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133784115 | CMS |
| Janssen Biotech, Inc. | $32.76 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078590009 | CMS |
| Janssen Biotech, Inc. | $38.71 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078590007 | CMS |
| Janssen Biotech, Inc. | $17.67 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078590004 | CMS |
| Phathom Pharmaceuticals, Inc. | $20.91 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151034614 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.99 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137469827 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.